STOCK TITAN
  1. Home
  2. News
  3. SGHT

Sight Sciences, Inc. - SGHT STOCK NEWS

Welcome to our dedicated page for Sight Sciences news (Ticker: SGHT), a resource for investors and traders seeking the latest updates and insights on Sight Sciences stock.

Sight Sciences, Inc. (SGHT) pioneers transformative ophthalmic devices for glaucoma and dry eye treatment, merging surgical precision with evidence-based therapeutic solutions. This page serves as the definitive source for SGHT-related news, offering stakeholders timely updates on advancements shaping eye care innovation.

Access press releases, clinical trial results, and regulatory milestones covering minimally invasive glaucoma surgery (MIGS) technologies like the OMNI Surgical System and the TearCare System for dry eye management. Our curated collection ensures professionals and investors stay informed about product approvals, peer-reviewed research, and strategic partnerships driving the company’s growth.

Explore updates across key areas including surgical device innovations, real-world clinical data, and regulatory filings. Each announcement is vetted for relevance, providing actionable insights into SGHT’s market position and technological leadership in interventional eyecare.

Bookmark this page for streamlined access to Sight Sciences’ latest developments. Regularly updated with authoritative content, it empowers users to track progress in ophthalmic treatment solutions backed by clinical validation and engineering excellence.

News

Sight Sciences Reports Fourth Quarter and Full Year 2023 Financial Results and Initiates Full Year 2024 Financial Guidance

Rhea-AI Summary
Sight Sciences, Inc. (SGHT) reported strong financial results for 2023, with $81.1 million in total revenue, a 14% increase from 2022. Operating expenses were reduced by 20% in Q4 2023. The company also secured a $65.0 million credit facility. Clinical trials showed positive results for OMNI and TearCare technologies, enhancing patient outcomes.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
6.09%
Tags
earnings
-
News

Sight Sciences to Report Fourth Quarter and Full Year 2023 Financial Results on March 7, 2024

Rhea-AI Summary
Sight Sciences, Inc. (SGHT) will report financial results for Q4 and full year 2023 on March 7, 2024. The company focuses on eyecare technology to enhance patient care. Investors can join the conference call for insights.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
3.02%
Tags
conferences earnings
-
News

Sight Sciences Announces European Launch of the Ergo-Series of the OMNI® Surgical System at the ESCRS Winter Meeting

Rhea-AI Summary
Sight Sciences, Inc. (Nasdaq: SGHT) launches the Ergo-Series of the OMNI Surgical System in Europe, enhancing minimally invasive glaucoma procedures. The technology aims to improve ergonomics and precision for surgeons, receiving positive feedback in the US and CE Mark approval for the EU market.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-0.7%
Tags
none
News

Sight Sciences Announces the Closing of up to $65 Million Senior Secured Credit Facility with Hercules Capital

Rhea-AI Summary
Sight Sciences, Inc. (SGHT) announced the closing of a $65 million senior secured credit facility with Hercules Capital, Inc. The transaction included an immediate draw of $35 million, used to pay off the principal amount of the Company’s indebtedness to its previous secured lender. The new facility strengthens the company's balance sheet and enhances its ability to execute its strategic plan. The capital commitment aims to help Sight Sciences deliver on its mission to transform the treatment of eye diseases by treating the underlying causes. The credit facility terms include a 54-month maturity, with an interest-only period of 30 months, which can be extended to 36 months subject to certain performance milestones.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-11.28%
Tags
none
-
News

Sight Sciences Announces Preliminary, Unaudited Fourth Quarter and Full Year 2023 Financial Highlights

Rhea-AI Summary
Sight Sciences, Inc. (Nasdaq: SGHT) reported preliminary financial highlights for Q4 and full year 2023, with total revenue expected to be $18.6-18.8 million for Q4, a 9% decrease, and $80.9-81.1 million for the full year, a 14% increase. Cash and cash equivalents as of Dec 31, 2023, were approximately $138 million. The company's Q4 and full year 2023 financial results are preliminary and subject to audit, with complete results expected in March 2024.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
5.11%
Tags
none
-
News

Sight Sciences Announces Withdrawal of Final LCDs on Micro-Invasive Glaucoma Surgery from Five Medicare Administrative Contractors

Rhea-AI Summary
Sight Sciences, Inc. (Nasdaq: SGHT) supports the decision by five Medicare Administrative Contractors to withdraw their final local coverage determinations for Micro-Invasive Glaucoma Surgery, ensuring continued access to comprehensive outflow procedure enabled by OMNI Surgical System technology for glaucoma patients.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-5.63%
Tags
none
News

Sight Sciences Announces the Publication of Successful Results of the SAHARA Randomized Controlled Clinical Trial Comparing TearCare® to Restasis® for the Treatment of Dry Eye Disease

Rhea-AI Summary
Sight Sciences, Inc. (Nasdaq: SGHT) announced the publication of the six-month primary results from the SAHARA randomized controlled trial, demonstrating the superior efficacy of interventional eyelid procedures enabled by TearCare technology over Restasis in addressing the underlying causes of evaporative dry eye.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
2.13%
Tags
clinical trial
-
News

Sight Sciences Announces the Acceptance for Publication of GEMINI 2, a Three Year, Prospective, Multicenter Trial Demonstrating Sustained, Significant IOP and Medication Reductions Enabled with the OMNI® Surgical System Technology

Rhea-AI Summary
Sight Sciences, Inc. (Nasdaq: SGHT) announced the acceptance for publication of the prospective, multi-center, three-year GEMINI 2 trial with long-term clinical outcomes for patients treated with the OMNI Surgical System technology. The trial demonstrated sustained and clinically significant intraocular pressure reduction of greater than 20% and clinically significant IOP lowering medication reduction at 36 months. The data further supports the need for continued access to OMNI technology.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
8.3%
Tags
none
-
News

Sight Sciences Reports Third Quarter 2023 Financial Results and Withdraws Guidance for Full Year 2023

Rhea-AI Summary
Sight Sciences, Inc. (Nasdaq: SGHT) reported Q3 2023 revenue of $20.0 million, a 7% increase YoY. The company withdrew its full year 2023 guidance due to uncertainties caused by a recent LCD that would limit Medicare patient access to a key procedure. The company also appointed a new Chief Commercial Officer and implemented cost-saving initiatives.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-1.9%
Tags
earnings
News

Sight Sciences to Report Third Quarter 2023 Financial Results on November 7, 2023

Rhea-AI Summary
Sight Sciences, Inc. will report financial results for Q3 2023 on November 7th. The company's management will discuss the results during a conference call.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
1.69%
Tags
conferences earnings
Stock SGHT logo
Sight Sciences, Inc.

Nasdaq:SGHT

SGHT Rankings

N/A Ranked by Market Cap
N/A Ranked by Dividends

SGHT Stock Data

136.54M
40.43M
20.6%
54.74%
3.04%
Medical Devices
Surgical & Medical Instruments & Apparatus
Link
United States
MENLO PARK